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nemia and Heart Failure
New Pathway?*
ary S. Francis, MD, FACC,
nne Kanderian, MD
leveland, Ohio
nemia is common among patients with heart failure,
robably occurring in approximately 20% of patients, de-
ending on the definition of terms and severity of patient
llness. Some anemia is likely dilutional (1), but most is
robably true anemia due to chronic disease or iron defi-
iency (2). The degree of anemia in patients with heart
ailure after acute myocardial infarction is associated with a
oor prognosis (3), and anemia in patients with chronic
eart failure from any cause has repeatedly been demon-
trated to predict a poor outcome (2). A consensus has
eemingly emerged in the heart failure community that
orrection of a reduced hemoglobin (Hb) level is an attrac-
ive therapeutic target deserving of further study. Of inter-
st, erythropoietin (EPO) levels are moderately elevated in
atients with heart failure, more so in very severe heart
ailure (4). This finding has not discouraged pharmaceutical
ompanies from testing the concept of using EPO and its
nalogues as possible treatment for heart failure. This is
learly a case where treatment precedes understanding of
athophysiology, a common occurrence throughout history.
See page 1657
The mechanism of the anemia in patients with heart
ailure and its role in the pathophysiology of heart failure
as been elusive. In some cases, the red blood cell mass is
ormal despite a low Hb level. Perhaps only 30% or fewer
ases are due to iron deficiency (2). However, using acute
hase reactants like serum transferrin might under-diagnose
ron deficiency anemia in patients with heart failure. The
revalence of iron deficiency anemia might in fact be greater
hen using transferrin saturation levels or bone marrow
spiration (5). Irrespective of the cause of low Hb, current
ata suggest that EPO and its analogs when given over
everal months might improve cardiac and renal function as
Editorials published in the Journal of American College of Cardiology reflect the views
f the authors and do not necessarily represent the views of JACC or the American
ollege of Cardiology.C
From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland,
hio. Dr. Francis is a consultant to Amgen.ell as exercise tolerance in patients with anemia and heart
ailure (6–9). Some of these studies combined use of EPO
ith intravenous iron (8,9). Controversy has arisen over
hether chronic EPO therapy is safe (10), because throm-
otic complications and hypertension have been reported in
atients with end-stage renal disease when this strategy is
mployed (11–13). A recent editorial called for a halt to the
REAT (Trial to Reduce Cardiovascular Events with
ranesp [darbepoietin alpha] Therapy) study. This siren
as in part based on a recent meta-analysis that casts doubt
n the role of targeting Hb concentrations when using EPO
n anemic patients with chronic kidney disease (14). Despite
uch concerns, a trial of darbepoietin alpha in patients with
nemia and heart failure (RED-HF [Reduction of Events
ith Darbepoietin in Heart Failure]) has now been
aunched, and until more data are forthcoming, we simply
on’t know about the long-term safety of this strategy in
atients with heart failure. Uncertainty about target Hb
evels remains challenging, but cold, hard facts are what we
eed. The trials of darbepoietin alpha should continue as
ong as their Data and Safety Monitoring Boards deem
hem safe to continue. Nevertheless, there is a certain
ncomfortableness about driving the Hb level too high with
PO or darbepoietin in patients with chronic kidney disease
r heart failure.
These uncertainties about whether and how to use
PO-like hormones to treat the anemia of heart failure
side, there are now 2 small published studies that report the
se of intravenous iron alone as a treatment strategy (15,16).
or many years, parenteral iron was considered dangerous,
ut with the emergence of iron saccharate (also known as
ron sucrose complex) there are far fewer serious adverse
ffects than with the older high-molecular-weight dextran
reparations (16). Nevertheless, acute myalgias (chest and
ack tightness) can occur. Bolger et al. (16) treated 16
nemic patients with heart failure with 1 g of iron sucrose by
olus intravenous injections over a 12-day treatment phase
n an outpatient setting. Mean follow-up was 92  6 days.
emoglobin improved, symptoms were reduced, and exer-
ise capacity was improved. There were no adverse effects.
ow we have a second small study. With a more traditional
andomized, placebo-controlled study design, Toblli et al.
15) studied 40 patients with heart failure and randomly
llocated treatment to isotonic saline or iron sucrose com-
lex 200 mg weekly infused over 60 min. Blinding was done
y putting a black cover around the intravenous (IV) bag, so
t is likely the research nurse was unblinded. Patients were
reated for 5 weeks with IV iron and followed for 5 months.
he treatment group improved in virtually all measured
arameters, including the N-terminal part of the pro-B-
ype natriuretic peptide (NT-proBNP), New York Heart
ssociation functional class, Minnesota Living with Heart
ailure Quality of Life Score, less diuretic requirement, less
eed for hospital stay, improved 6-min walk test, lower
-reactive protein, reduced creatinine clearance, and im-
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October 23, 2007:1666–7 Editorial Commentroved left ventricular ejection fraction. One seldom sees
uch remarkably consistent improvement in all measure-
ents in small studies such as this, but the results coupled
ith the observations of Bolger et al. (16) do suggest that
urther studies in this field might be fruitful.
The dramatic reduction in NT-proBNP is surprising
ith IV iron, because few therapies have previously dem-
nstrated such long-term improvement in natriuretic pep-
ides. The tight correlations between NT-proBNP and Hb
re also surprising. Most correlations seen in interventional
eart failure studies are far less striking. However, anemia is
ssociated with elevated plasma B-type natriuretic peptide
ith or without heart failure (17,18), and it is possible that
imply correcting the Hb leads directly to reduced NT-
roBNP, whereas simultaneous improvement in the heart
ailure condition might further drive down the plasma
atriuretic peptide levels.
These 2 clinical studies using IV iron to treat heart failure
re important, because they raise the possibility that an
lternative strategy different than that of using EPO analogs
o treat patients with heart failure and anemia might work.
iving IV iron sucrose complex might prove to be more
fficacious, safer, and less costly than employing long-term
arbepoietin alpha. It is too early to tell. It should be kept
n mind that EPOs might have additional, non-hematological
ffects. Antiapoptotic, mitogenic, and angiogenic activities
an occur (19). Some of the non-hematologic “unintended
ffects” might be favorable, and some might not. We simply
o not know.
We look forward to additional studies with IV iron. Only
arger, more robust clinical trials with IV iron will allow
onfidence to emerge. We also need the large trials using
PO analogs to continue, because we will learn from these
xperiences. Nevertheless, small observational clinical stud-
es done by single centers with novel strategies still play an
mportant role in the ever-changing picture of therapy for
hronic disease. These small studies seed the open mind to
ew ideas, allowing the construction of creative hypotheses
o be eventually tested in a more expansive and scientifically
ound manner. We now have 2 such studies. We look
orward to further replication. (20).
eprint requests and correspondence: Dr. Gary S. Francis, 9500
uclid Avenue, F15 Cleveland, Ohio 44195. E-mail: francig@ccf.org.
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